Precision BioSciences, Inc. (DTIL)
| Market Cap | 519.42M |
| Revenue (ttm) | 24.29M |
| Net Income (ttm) | -109.01M |
| Shares Out | 52.03M |
| EPS (ttm) | -2.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $9.27 |
| Previous Close | $8.93 |
| Change ($) | 0.34 |
| Change (%) | 3.81% |
| Day's Open | 9.02 |
| Day's Range | 8.83 - 9.50 |
| Day's Volume | 858,066 |
| 52-Week Range | 4.46 - 16.60 |
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 32.65% and 86.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were up 36.54% year over year to ($0.33), which beat the estimate...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...
Precision BioSciences Inc (NASDAQ: DTIL) has announced new in vivo data using ARCUS genome editing platform resulting from a preclinical research collaboration with investigators at the University of Pe...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, announced today that ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome ...
DURHAM, N.C.--(BUSINESS WIRE)--Stanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences.
DURHAM, N.C.--(BUSINESS WIRE)--Derek Jantz, CSO and Co-Founder of Precision BioSciences, will participate in a fireside chat at Truist Securities Life Sciences Virtual Series.
Begins Search for Next Chief Executive Officer Begins Search for Next Chief Executive Officer
DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with...
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 12.00% and 136.97%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Precision BioSciences (NASDAQ:DTIL) moved higher by 2.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 22.22% year over year to ($...
DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 f...
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision BioSciences Inc (NASDAQ: DTIL) has announced three-year follow-up data showing long-term stable reduction of low-density lipoprotein (LDL) cholesterol levels in nonhuman primates (NHPs) after ...
Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, a...
Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin by mid-2021 Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin ...
DURHAM, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genom...
DTIL has three business lines, all of which include important collaborations with large companies. Recent results in CAR-T therapies have been very encouraging.
DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome...
Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS)
DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genom...
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive lice...
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 26.47% and 73.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Precision BioSciences (NASDAQ:DTIL) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 21.95% year over year to ($0.50), which beat the e...
Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genom...
Precision Bio: 2020 Is Not Looking Great With 2 Terminated Partnerships And Cash Down -30% To $127M.
Precision BioSciences, Inc. is a life sciences company focused on utilizing its ARCUS genome editing platform to primarily treat human diseases and secondarily to provide food/agricultural solutions. Pr...
PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings
DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with ...
DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies wi...
Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR...
A key update from the U.S. Food and Drug Administration (FDA) boosted Precision BioSciences Inc.
DURHAM, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® ge...
DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® ge...
DURHAM, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® gen...
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -5.00% and -80.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q2 results.
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® gen...
DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® gen...
-PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic –
About DTIL
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with re... [Read more...]
| Industry Biotechnology | IPO Date Mar 28, 2019 |
| CEO Matthew Kane | Employees 231 |
| Stock Exchange NASDAQ | Ticker Symbol DTIL |
Financial Performance
In 2020, DTIL's revenue was $24.29 million, an increase of 9.20% compared to the previous year's $22.24 million. Losses were -$109.01 million, 17.4% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is 18.63, which is an increase of 100.97% from the latest price.